IGFBP-3 Interpretation by Decade of Life

IGFBP-3 (insulin-like growth factor binding protein 3) serves as the primary carrier protein that transports IGF-1 through the bloodstream; the majority of circulating IGF-1 exists in a bound state to IGFBP-3 rather than circulating freely. As a measured serum marker rather than a therapeutic agent, hormone, or independent clinical diagnosis, IGFBP-3 functions as a diagnostic tool measured together with IGF-1 to assess the functional status of the growth hormone (GH) axis. This marker differs from IGF-1 itself, from GH, and from compounds that stimulate GH release such as sermorelin or CJC-1295/ipamorelin, which represent distinct substances addressed separately in this article.

The direct answer

There is no single IGFBP-3 number that applies across all ages, and the exact ng/mL boundaries printed in most patient-facing charts, including earlier versions of this page, vary meaningfully by assay platform. What is well established is the direction of change: IGFBP-3 rises through childhood and puberty, peaks in early adulthood, and declines gradually from the mid-twenties onward as part of normal aging of the GH axis. What is not established, or is actively debated, is whether raising IGFBP-3 in an otherwise healthy older adult with a low-normal value produces any meaningful health benefit. A confirmed diagnosis of GH deficiency in an adult requires a low IGF-1 and/or IGFBP-3 in the appropriate clinical context plus a failed GH stimulation test, not a single low IGFBP-3 result on its own.

What IGFBP-3 measures and why it is paired with IGF-1

GH is released in pulses from the pituitary gland and stimulates the liver to produce both IGF-1 and IGFBP-3. Because IGFBP-3 circulates with a longer half-life than GH itself, it smooths out some of the pulsatility and can act as a more stable marker of average GH exposure over the prior day or two than a single GH measurement would be.

Neither IGF-1 nor IGFBP-3 alone tells the full story. Malnutrition, liver disease, and insulin resistance can each suppress IGFBP-3 somewhat independently of true GH status, which can create a mismatch between the two markers. Clinical guidance on adult GH deficiency evaluation generally supports checking both IGF-1 and IGFBP-3 together rather than relying on either one in isolation, because a discordant pattern (for example, low IGFBP-3 with a normal IGF-1) more often points toward a non-GH cause such as liver dysfunction or hyperinsulinemia than toward pituitary disease. The exact wording of any specific society guideline should be confirmed against the current published version before it is quoted to a patient or used to justify treatment.

Assay variability across laboratories

Reference ranges differ between laboratory platforms, and a numeric IGFBP-3 result from one lab is not automatically comparable to the same number from a different lab. This is a well-recognized limitation of IGF-1/IGFBP-3 immunoassays generally. In practice this means the reference range printed directly on your lab report, not a generic chart, is the correct comparison for your result, and trending a value over time is only meaningful if the same lab and platform are used each time.

How IGFBP-3 changes by decade of life

Age is the strongest predictor of IGFBP-3 concentration in people without GH axis disease. The pattern below describes the general shape of that age-related change. Exact ng/mL cutoffs vary enough between assay platforms that we are presenting this as a directional pattern rather than a set of authoritative numbers; treat any specific figure here as illustrative and verify current cutoffs against your own lab's reported reference range before drawing conclusions.

Childhood and adolescence (roughly ages 0-19). IGFBP-3 is low in early childhood, rises through mid-childhood, and increases sharply around puberty as sex-hormone-driven GH pulsatility increases. Pediatric GH deficiency is generally suspected when IGFBP-3 (or IGF-1) falls well below the age- and sex-specific expected range, interpreted by a pediatric endocrinologist alongside growth velocity and bone age, not from the lab value alone.

Twenties. This decade represents the physiologic ceiling for most people. GH secretion and sleep-dependent GH pulses are typically at or near their lifetime peak, and sex hormones amplify hepatic IGF-1 and IGFBP-3 output, which is part of why male and female reference ranges diverge more clearly here than in childhood.

Thirties through fifties. IGFBP-3 begins a gradual, roughly linear decline that continues for the rest of adulthood in most people. This is also the period when metabolic conditions such as insulin resistance become more common and can independently suppress IGFBP-3, which complicates interpretation of a low value in this age range. A low result in someone with new fatigue, reduced exercise recovery, or unexplained body composition change is a reasonable trigger for a broader GH-axis workup, but it is not itself diagnostic of anything.

Sixties and beyond. Reference ranges reach their lowest point in this stage of life. Some adults are diagnosed with GH deficiency for the first time in their sixties, when accumulated pituitary changes finally push their axis below stimulation-test thresholds after decades of borderline function. Population studies have also examined associations between low IGF-1/IGFBP-3 and cardiovascular or all-cause mortality risk in older adults; these are observational associations, the specific cohort studies and effect sizes referenced in earlier material could not be verified for this draft, and association does not establish that raising IGFBP-3 would change that risk.

Because of the platform variability described above, we have removed the specific ng/mL-by-decade table that appeared in an earlier version of this article rather than present numbers we cannot verify as authoritative. If you want age- and sex-matched numeric ranges, ask your ordering lab or clinician for the reference interval used by the specific assay that ran your test.

Is there an "optimal" IGFBP-3, separate from normal?

Lab reference ranges describe the middle of a tested population, which includes people with subclinical GH deficiency, obesity, and metabolic disease mixed in with people who have no GH axis problem at all. Some longevity-focused and anti-aging medicine practitioners target the upper third of the age-matched reference interval as a treatment goal rather than simply staying above the lower limit. This is a clinical opinion and site-level judgment held by a subset of practitioners, not a position adopted by mainstream endocrine guidelines, and it should be labeled as such to patients.

A small clinical study in GH-deficient adults receiving GH replacement has been cited as showing better quality-of-life scores in patients titrated to upper-normal IGF-1 compared with lower-normal, even within the technically normal range. We were not able to verify the specific study, sample size, or effect size behind that claim for this draft, so it should be treated as a plausible but unconfirmed rationale rather than settled evidence, and it applies to GH-deficient patients on replacement therapy, not to healthy adults seeking to raise a low-normal value.

Cancer risk is a real consideration, not a footnote

The relationship between the GH/IGF-1 axis and cancer risk is genuinely debated and should not be waved away when discussing "optimal" targets. Higher circulating IGF-1 has been associated with modestly increased prostate cancer risk in observational research, and some data suggest IGFBP-3 may be weakly protective by binding free IGF-1 and limiting receptor activation. The specific meta-analysis and relative-risk figure cited in earlier material could not be verified for this draft and are not repeated here. The practical takeaway that does not depend on any single disputed number is this: deliberately pushing IGFBP-3 or IGF-1 above the normal range through GH therapy is not a recommended strategy, and anyone on GH replacement with a personal or family history of hormone-sensitive cancer should discuss that history explicitly with the prescribing clinician before starting or continuing treatment.

A decision framework for interpreting an IGFBP-3 result

Use this sequence before deciding what a given IGFBP-3 result means. It does not replace clinical judgment or a formal endocrine workup, and it is not a substitute for individualized dosing or diagnosis.

1. Confirm you are comparing against the correct reference range. Use the range printed on the specific lab report, not a generic age chart. If tracking a trend, confirm the same lab and assay platform was used each time.
2. Check IGF-1 on the same sample. If both are low together, GH axis suppression (true deficiency or an acquired confounder) is more likely. If IGFBP-3 is low but IGF-1 is normal, suspect a non-GH cause first.
3. Screen for the five common non-GH suppressors before blaming the pituitary: liver disease (check AST/ALT and consider hepatic workup if abnormal), insulin resistance or obesity, recent caloric restriction or very-low-calorie dieting, uncorrected hypothyroidism, and chronic kidney disease. Correct or account for any of these before repeating GH-axis testing.
4. Weigh symptoms against the age-adjusted percentile, not the absolute number. A result in the lower quartile for a 35-year-old is a different clinical situation than the same absolute number in a 72-year-old, even if the raw ng/mL figure looks alarming out of context.
5. Decide whether a GH stimulation test is warranted. Two separate low IGF-1/IGFBP-3 values plus a clinical picture consistent with GH deficiency are grounds to consider formal biochemical testing (such as the insulin tolerance test or glucagon stimulation test) rather than treating from the screening labs alone (Diagnosis of adult GH deficiency, 2008).
6. If considering an intervention for a low-normal value without confirmed GH deficiency, recognize this as an off-label or longevity-medicine decision outside FDA-approved indications for somatropin, weigh the absence of long-term outcome data, and treat cancer history and metabolic status as factors that change the risk-benefit calculation.

When to seek urgent rather than routine care: IGFBP-3 interpretation is never an emergency by itself. Seek urgent evaluation instead of waiting on lab interpretation if there are symptoms suggestive of a pituitary mass or acute pituitary event, such as new severe headache, sudden vision change, or new diabetes insipidus-type symptoms (extreme thirst and urination), since these require imaging and specialist evaluation regardless of any IGFBP-3 value.

Non-GH causes of a low IGFBP-3

At least five conditions can suppress IGFBP-3 without a true GH deficiency being present, and each should be considered before attributing a low result to pituitary disease or to age-related decline:

• Liver disease. IGFBP-3 is synthesized almost entirely in the liver, so cirrhosis, fatty liver disease, and viral hepatitis can lower it independent of GH status.
• Insulin resistance and obesity. Hyperinsulinemia is associated with reduced hepatic GH receptor sensitivity, and IGFBP-3 is often lower in people with significant insulin resistance even when GH secretion tests normal.
• Malnutrition and caloric restriction. Acute negative energy balance induces a state of GH resistance in the liver, lowering IGFBP-3 even though GH secretion itself may be elevated. This matters for patients on very-low-calorie diets or with eating disorders.
• Uncorrected hypothyroidism. Thyroid hormone supports GH receptor signaling, so significant hypothyroidism can lower IGFBP-3; correcting thyroid status before retesting is standard practice in a GH-axis workup.
• Chronic kidney disease. Reduced hepatic synthesis and altered clearance of IGF-binding complexes can lower both IGF-1 and IGFBP-3 independent of the pituitary.

Specific percentage magnitudes for each of these effects appeared in earlier drafts of this article; because the underlying citations could not be verified, we describe the direction of each effect here without a specific percentage, and any number your clinician cites for a specific condition should be checked against current primary literature.

IGFBP-3 in GH replacement therapy monitoring

When a patient is prescribed GH replacement (somatropin) for a confirmed indication such as documented adult or pediatric GH deficiency, IGF-1 and IGFBP-3 are the primary serum markers used to titrate dose, alongside symptoms and side effects such as fluid retention, joint aches, or carpal tunnel symptoms. IGFBP-3 typically functions as a secondary, confirmatory marker while IGF-1 carries more weight in most titration protocols. Dosing decisions, starting doses, and titration schedules are individualized by the prescribing endocrinologist and are not something this article can specify for any individual patient. Somatropin is FDA-approved for a defined set of indications, including confirmed GH deficiency, and current label details should be confirmed through the FDA's Drugs@FDA database rather than assumed from secondary sources, since labels are periodically updated.

IGFBP-3 and longevity medicine: what is established versus speculative

Some clinicians describe the gradual, age-related decline in GH pulsatility and downstream IGF-1/IGFBP-3 as "somatopause." This is a descriptive term for a well-observed pattern of decline, not a distinct diagnosis, and its clinical significance in someone without confirmed pituitary disease is unresolved.

In practice, some longevity-medicine providers use GH secretagogues (such as sermorelin or CJC-1295/ipamorelin combinations) off-label in adults without confirmed pituitary disease, aiming to raise endogenous GH pulsatility and IGFBP-3 toward the upper part of the age-matched range. This is an off-label use of compounds outside their approved indications, delivered in some cases as compounded preparations, and it differs materially from FDA-approved somatropin therapy for confirmed GH deficiency. No large randomized controlled trial has demonstrated that normalizing IGFBP-3 in healthy older adults with low-normal values extends lifespan, reduces all-cause mortality, or produces benefits that outweigh the unknown long-term risks of chronic GH-axis stimulation. Anyone considering this route should understand it as an evidence gap, not a confirmed benefit, and should discuss individual risk factors, including cancer history and metabolic status, with a clinician before proceeding.

Practical checklist before drawing IGFBP-3

• Fast for at least 8 hours before the draw to reduce postprandial confounding of GH-axis markers.
• Draw in the morning when possible, since GH pulsatility is influenced by the sleep-wake cycle.
• Note any recent use of glucocorticoids, estrogen therapy, or high-dose insulin, since each can independently shift IGFBP-3.
• Order IGF-1 on the same sample rather than as a separate draw on a different day.
• Record age, sex, and relevant comorbidities on the lab order so the correct reference range is applied.
• If tracking a trend, use the same lab and assay platform each time.
• A single low IGFBP-3 result, without corroborating IGF-1 suppression, clinical symptoms, and (when GH deficiency is suspected) a failed stimulation test, does not by itself diagnose GH deficiency (Diagnosis of adult GH deficiency, 2008).

Evidence boundary

Established: IGFBP-3 is the main IGF-1 carrier protein; it rises through puberty, peaks in early adulthood, and declines with age in most people; liver disease, malnutrition, hypothyroidism, kidney disease, and insulin resistance can each lower it independent of true GH status; confirming adult GH deficiency requires biochemical testing beyond a single screening value.

Plausible but unproven: that targeting the upper third of an age-matched IGFBP-3 range produces meaningful functional or longevity benefit in people without confirmed GH deficiency; that off-label GH secretagogue use meaningfully and safely raises IGFBP-3 toward that target over the long term.

Not established: that raising a low-normal IGFBP-3 in an otherwise healthy older adult extends lifespan or reduces mortality; precise, platform-independent ng/mL cutoffs by decade that would apply across all labs.